EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study

Claire Kim, Mark Higgins, Lingyun Liu, Nataliya Volkova, Anna Zolin, Lutz Naehrlich, ECFSPR Study Group

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.02.004 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Claire Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, Boston, MA, USA. Electronic address: Claire_Kim@vrtx.com. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Registries, Disease Progression. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lumacaftor/ivacaftor (LUM/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (CF) ≥1 year of age. To assess the impact of early LUM/IVA initiation on CF disease progression, a 6-year observational study leveraging data from existing CF patient registries is being conducted in children with CF homozygous for F508del (F/F genotype) who were aged 2 through 5 years at treatment initiation. Here we present interim results from this study focusing on data from the European CF Society Patient Registry (ECFSPR). METHODS: The LUM/IVA cohort included children in the ECFSPR who started LUM/IVA between 15 January 2019 and 31 December 2020. Longitudinal trends in growth parameters, pulmonary exacerbations, hospitalizations, safety outcomes, and other effectiveness outcomes in the LUM/IVA cohort were compared to those in two modulator-naïve cohorts: (i) matched concurrent cohort heterozygous for F508del and a minimal function mutation (F/MF concurrent comparator cohort) and (ii) matched concurrent cohort with the F/F genotype from countries without commercial access to LUM/IVA as of 2020 (F/F concurrent comparator cohort). RESULTS: The LUM/IVA cohort matched to the F/MF concurrent comparator cohort had 681 children and the LUM/IVA cohort matched to the F/F concurrent comparator cohort had 183 children. LUM/IVA cohorts had increases in body mass index percentiles relative to the matched F/MF and F/F concurrent comparator cohorts (mean difference in change from baseline: 8.4 [95% CI: 5.5, 11.3] and 11.8 [95% CI: 5.9, 17.7], respectively). Increases in height and weight percentiles were also observed in the LUM/IVA cohort relative to the F/MF and F/F concurrent comparator cohorts. Reductions in pulmonary exacerbations and hospitalizations relative to baseline and the F/F concurrent comparator cohort were seen in 2021. CONCLUSIONS: This interim analysis showed favorable trends in clinical outcomes, including growth parameters, pulmonary exacerbations, and hospitalizations, suggesting an early beneficial effect of LUM/IVA treatment in children aged 2 through 5 years at treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsRegistriesDisease ProgressionAminopyridinesDrug CombinationsBenzodioxolesQuinolonesHumansFemaleChild, PreschoolMaleCystic Fibrosis Transmembrane Conductance RegulatorChloride Channel AgonistsTreatment Outcome

Stichwörter der Autor:innen

CFTR modulatorsCFTR therapiesChildrenCystic fibrosisIvacaftorLumacaftor

Substanzen

AminophenolsAminopyridineslumacaftor, ivacaftor drug combinationDrug CombinationsBenzodioxolesQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorChloride Channel Agonists

Autor:innen und Institutionen

  • Vertex Pharmaceuticals Incorporated, Boston, MA, USA. Electronic address: Claire_Kim@vrtx.com.
  • Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.

Förderung

  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Kim, C., Higgins, M., Liu, L., Volkova, N., Zolin, A., Naehrlich, L., & ECFSPR Study Group (2024). Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.02.004

Vancouver

Kim C, Higgins M, Liu L, Volkova N, Zolin A, Naehrlich L, et al. Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.02.004

BibTeX
@article{Kim2024,
  author = {Kim, Claire and Higgins, Mark and Liu, Lingyun and Volkova, Nataliya and Zolin, Anna and Naehrlich, Lutz and ECFSPR Study Group, ECFSPR Study Group},
  title = {Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.02.004}
}
Kostenlos starten →